Last reviewed · How we verify
Epidural Bupivacaine plus fentanyl — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Epidural Bupivacaine plus fentanyl (Epidural Bupivacaine plus fentanyl) — University of Texas Southwestern Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epidural Bupivacaine plus fentanyl TARGET | Epidural Bupivacaine plus fentanyl | University of Texas Southwestern Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epidural Bupivacaine plus fentanyl CI watch — RSS
- Epidural Bupivacaine plus fentanyl CI watch — Atom
- Epidural Bupivacaine plus fentanyl CI watch — JSON
- Epidural Bupivacaine plus fentanyl alone — RSS
Cite this brief
Drug Landscape (2026). Epidural Bupivacaine plus fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/epidural-bupivacaine-plus-fentanyl. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab